Mechanism #
Serotonin/noradrenaline reuptake inhibitor.
Clinical distinction #
Selected US extended-release product is indicated for adult MDD.
Monitoring and warnings #
Blood pressure/pulse, urinary hesitation, renal dose restrictions and discontinuation symptoms.
Formulation scope #
Extended-release oral capsule.
Dose reference #
| Indication | Population | Formulation / route | Jurisdiction | Reference |
|---|---|---|---|---|
| MDD | Adults; general label population only. See separate impairment/age restrictions. | FETZIMA oral extended-release capsule · oral | United States | Adult labelled initiation 20 mg/day for two days, then 40 mg/day; range 40–120 mg/day. Increases of 40 mg are separated by at least two days. Renal/interaction limits differ. |
Special populations & counseling #
Age, renal and hepatic function, pregnancy, breastfeeding, co-medication and the treatment indication require medicine-specific review. A general class statement cannot establish suitability for an individual.
Discuss the intended benefit, expected review plan, relevant adverse effects, driving or falls considerations, and how to obtain help. Stopping, switching or restarting requires the exact product’s instructions and clinical assessment.
Brands & products #
Supplied catalogue observations; price dates may be unknown. Presence does not establish current stock or Indian approval.
Reference coverage #
Ingredient profiles and product records are separate. Details not supplied in this reference must be checked in the exact product information; missing information is not evidence of absence or safety.
References · 3
- DailyMed structured product information · Retrieved 2026-10-07
- MHRA product information · Retrieved 2026-10-07
- CDSCO approved new drugs · Retrieved 2026-10-07